p53 upregulates death receptor 4 expression through an intronic p53 binding site

Cancer Research

Volumn 64, Issue 15, 2004, Pages 5078-5083

  Liu, Xiangguo ^a   Yue, Ping ^a   Khuri, Fadlo R ^a   Sun, Shi Yong ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEATH RECEPTOR 4; DEATH RECEPTOR 5; DNA; LUCIFERASE; PROTEIN P53; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; BINDING SITE; CHROMATIN; CONTROLLED STUDY; DNA DAMAGE; GENE EXPRESSION REGULATION; GENE LOCUS; GENETIC TRANSCRIPTION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; MOLECULAR CLONING; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; REPORTER GENE; SIMIAN VIRUS 40;

BINDING SITES; BREAST NEOPLASMS; CHROMATIN; DNA; DNA DAMAGE; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTRONS; LUCIFERASES; PRECIPITIN TESTS; PROMOTER REGIONS (GENETICS); RECEPTORS, TUMOR NECROSIS FACTOR; TRANS-ACTIVATION (GENETICS); TRANSCRIPTION, GENETIC; TRANSFECTION; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53; UP-REGULATION;

EID: 3442884825     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-04-1195     Document Type: Article

References (29)

1. Vousden KH, Lu X. Live or let die: the cell's response to p53. Nat Rev Cancer 2002;2:594-604.
2. Oren M. Decision making by p53: life, death and cancer. Cell Death Differ 2003;10:431-42.
3. El-Deiry WS. Insights into cancer therapeutic design based on p53 and TRAIL receptor signaling. Cell Death Differ 2001;8:1066-75.
4. Ashkenazi A, Pai RC, Fong S, et al. Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Investig 1999;104:155-62.
5. Walczak H, Miller RE, Ariail K, et al. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med 1999;5:157-63.
6. Ashkenazi A, Dixit VM. Death receptors: signaling and modulation. Science 1998;281:1305-8.
7. Wajant H, Pfizenmaier K, Scheurich P. TNF-related apoptosis inducing ligand (TRAIL) and its receptors in tumor surveillance and cancer therapy. Apoptosis 2002;7:449-59.
8. Wu GS, Burns TF, McDonald ER 3rd, et al. KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor gene. Nat Genet 1997;17:141-3.
9. Takimoto R, El-Deiry WS. Wild-type p53 transactivates the KILLER/DR5 gene through an intronic sequence-specific DNA-binding site. Oncogene 2000;19:1735-43.
10. Guan B, Yue P, Clayman GL, Sun S-Y. Evidence that death receptor DR4 is a DNA damage-inducible, p53-regulated gene. J Cell Physiol 2001;188:98-105.
11. Bartke T, Siegmund D, Peters N, et al. p53 upregulates cFLIP, inhibits transcription of NF-κB-regulated genes and induces caspase-8-independent cell death in DLD-1 cells. Oncogene 2001;20:571-80.
12. Wosik K, Antel J, Kuhlmann T, Bruck W, Massie B, Nalbantoglu J. Oligodendrocyte injury in multiple sclerosis: a role for p53. J Neurochem 2003;85:635-44.
13. Liu Q, El-Deiry WS, Gazitt Y. Additive effect of Apo2L/TRAIL and Adeno-p53 in the induction of apoptosis in myeloma cell lines. Exp Hematol 2001;29:962-70.
14. Jang SH, Seol JY, Kim CH, et al. Additive effect of TRAIL and p53 gene transfer on apoptosis of human lung cancer cell lines. Int J Mol Med 2004;13:181-6.
15. Song JH, Song DK, Pyrzynska B, Petruk KC, Van Meir EG, Hao C. TRAIL triggers apoptosis in human malignant glioma cells through extrinsic and intrinsic pathways. Brain Pathol 2003;13:539-53.
16. Sheikh MS, Huang Y, Fernandez-Salas EA, et al. The antiapoptotic decoy receptor TRID/TRAIL-R3 is a p53-regulated DNA damage-inducible gene that is overexpressed in primary tumors of the gastrointestinal tract. Oncogene 1999;18:4153-9.
17. Meng RD, McDonald ER 3rd, Sheikh MS, Fornace AJ Jr, El-Deiry WS. The TRAIL decoy receptor TRUNDD (DcR2, TRAIL-R4) is induced by adenovirus-p53 overexpression and can delay TRAIL-, p53-, and KILLER/DR5-dependent colon cancer apoptosis. Mol Ther 2000;1:130-44.
18. Ruiz De Almodovar C, Ruiz-Ruiz C, Rodriguez A, et al. TRAIL decoy receptor TRAIL-R3 is upregulated by p53 in breast tumor cells through a mechanism involving an intronic p53 binding site. J Biol Chem 2004;279:4093-101.
19. Sheikh MS, Fornace AJ Jr. Death and decoy receptors and p53-mediated apoptosis. Leukemia 2000;14:1509-13.
20. Ozoren N, El-Deiry WS. Cell surface death receptor signaling in normal and cancer cells. Semin Cancer Biol 2003;13:135-47.
21. Sun SY, Yue P, Wu GS, et al. Mechanisms of apoptosis induced by the synthetic retinoid CD437 in human non-small cell lung carcinoma cells. Oncogene 1999;18:2357-65.
22. Pfahl M, Tzukerman M, Zhang X-K, et al. Nuclear retinoic acid receptors: cloning, analysis, and function. Methods Enzymol 1990;189:256-71.
23. El-Deiry WS, Kern SE, Pietenpol JA, Kinzler KW, Vogelstein B. Definition of a consensus binding site for p53. Nat Genet 1992;1:45-9.
24. Burns TF, Bernhard EJ, El-Deiry WS. Tissue specific expression of p53 target genes suggests a key role for KILLER/DR5 in p53-dependent apoptosis in vivo. Oncogene 2001;20:4601-12.
25. Wang S, El-Deiry WS. Requirement of p53 targets in chemosensitization of colonic carcinoma to death ligand therapy. Proc Natl Acad Sci USA 2003;100:15095-100.
26. Kim K, Fisher MJ, Xu SQ, El-Deiry WS. Molecular determinants of response to TRAIL in killing of normal and cancer cells. Clin Cancer Res 2000;6:335-46.
27. Ozoren N, Fisher MJ, Kim K, et al. Homozygous deletion of the death receptor DR4 gene in a nasopharyngeal cancer cell line is associated with TRAIL resistance. Int J Oncol 2000;16:917-25.
28. Aza-Blanc P, Cooper CL, Wagner K, Batalov S, Deveraux QL, Cooke MP. Identification of modulators of TRAIL-induced apoptosis via RNAi-based phenotypic screening. Mol Cell 2003;12:627-37.
29. Kim K, Takimoto R, Dicker DT, Chen Y, Gazitt Y, El-Deiry WS. Enhanced TRAIL sensitivity by p53 overexpression in human cancer but not normal cell lines. Int J Oncol 2001;18:241-7.